WO2026053108 - METHOD OF TREATMENT
National phase entry is expected:
Publication Number
WO/2026/053108
Publication Date
12.03.2026
International Application No.
PCT/IB2025/058834
International Filing Date
02.09.2025
Title **
[English]
METHOD OF TREATMENT
[French]
MÉTHODE DE TRAITEMENT
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
Inventors
CHAN, Robert
MAYER, Bhabita
MOUNEIMNE, Dalal
Priority Data
63/690,259
03.09.2024
US
63/733,725
13.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2800 | |
| EPO | Filing, Examination, Granting | 17399 | |
| Japan | Filing, Examination, Granting | 2670 | |
| South Korea | Filing, Examination, Granting | 3082 | |
| USA | Filing, Examination, Granting | 8740 |
Total:
34,691
Contact Us
Abstract[English]
The present invention relates to methods of treating chronic obstructive pulmonary disesse (COPD) in an enhanced patient population, particularly by administering an anti- IL5 antibody or fragment thereof.[French]
La présente invention concerne des méthodes de traitement de la bronchopneumopathie chronique obstructive (BPCO) dans une population de patients améliorée, en particulier par administration d'un anticorps anti-IL5 ou d'un fragment de celui-ci.